Premenstrual syndrome

2011 ◽  
pp. 1197-1206
Author(s):  
Andrea Rapkin ◽  
Mya Zapata
Keyword(s):  
Diagnostic Criteria ◽  
Premenstrual Syndrome ◽  
Premenstrual Dysphoric Disorder ◽  
Severe Form ◽  
Pharmacological Management ◽  
Workplace Productivity ◽  
Affective Symptoms ◽  
Clinician Education ◽  
Criteria For Diagnosis ◽  
Reproductive Aged Women

The premenstrual disorders, premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are psychoneuroendocrine disorders characterized by a constellation of affective, somatic, and behavioural symptoms that occur monthly, during the luteal phase of the menstrual cycle with relief soon after the onset of menses. PMS affects approximately 15–40% of reproductive aged women depending on criteria for diagnosis. PMDD is a severe form of PMS, with an emphasis on the affective symptoms. It has been estimated that only 5–8% of women meet the strict criteria for PMDD, but up to 20% may be one symptom short of meeting the criteria (1). The premenstrual syndromes adversely impact relationships, activities of daily living, and workplace productivity. The research and treatment of the premenstrual disorders have been hampered by lack of consensus regarding the specific diagnostic criteria, methods of assessment of symptoms and impairment, and absence of animal models or biological markers for the disorders. However, elucidation of various aspects of the pathophysiology, well designed multicentre treatment trials, and patient and clinician education have successfully improved diagnosis and management This chapter will review symptoms, definitions, diagnostic criteria, aetiology, evaluation, and nonpharmacological and pharmacological management of PMS and PMDD.

scholarly journals Ethinyl Estradiol/Drospirenone for the Treatment of the Emotional and Physical Symptoms of Premenstrual Dysphoric Disorder

2007 ◽  
Vol 3 (4) ◽  
pp. 395-408 ◽  
Author(s):  
Andrea J Rapkin ◽  
Michelle McDonald ◽  
Sharon A Winer
Keyword(s):  
Premenstrual Syndrome ◽  
Ethinyl Estradiol ◽  
Oral Contraceptive Pill ◽  
Premenstrual Dysphoric Disorder ◽  
Physical Symptoms ◽  
Severe Form ◽  
Steroid Production ◽  
Combined Oral Contraceptive ◽  
Free Interval ◽  
Affective Symptoms

A combined oral contraceptive pill containing 20 μg of ethinyl estradiol and 3 mg of the progestin drospirenone in a novel dose regimen (24 active pills followed by 4 placebo pills), has demonstrated efficacy for the symptoms of premenstrual dysphoric disorder, a severe form of premenstrual syndrome, with an emphasis on the affective symptoms. Drospirenone has progestagenic, anti-androgenic and anti-aldosterone properties, which differ from earlier generations of progestins, and reducing the hormone pill-free interval allows for better suppression of ovarian steroid production.

scholarly journals PREMENSTRUAL SYNDROME: CLINICAL PATTERN, DIAGNOSTICS AND THERAPEUTIC APPROACHES

2017 ◽  
pp. 106-111
Author(s):  
L. P. Guliyeva ◽  
S. V. Yureneva
Keyword(s):  
Premenstrual Syndrome ◽  
Premenstrual Dysphoric Disorder ◽  
Severe Form ◽  
Reproductive Age ◽  
Therapeutic Approaches ◽  
First Line ◽  
Women Of Reproductive Age ◽  
Psychoneurological Symptoms ◽  
Regular Mode ◽  
Line Drug

Premenstrual syndrome (PMS) is a complex, cyclical, polyethiological, multifactorial combination of physical and mental disorders that occur in some women of reproductive age in the second - luteal - phase of the menstrual cycle and negatively affect the woman’s usual lifestyle.Premenstrual dysphoric disorder (PMDD) is a severe form of PMS in which psychoneurological symptoms prevail. For the diagnosis of PMDD, the specific DSM-5 criteria were developed by the American Psychiatric Association according to which the the diagnosis is confirmed by the presence of five or more symptoms in women during the week prior to menstruation and their disappearance a few days after the onset of menstruation. These symptoms are observed for at least two cycles.Treatment of women with PMS/PMDD, first of all, should start with the lifestyle adjustment, inclusion of regular mode rate physical activity into daily activities. The effectiveness of vitamins B6, E and calcium has not been confirmed in studies. First-line drug therapy includes SSRIs or combined oral contraceptives containing drospirenone are prescribed first, then agonists of gonadotropin-releasing hormone.

scholarly journals Premenstrual Syndrome: Correlation and Functional Impairment

2017 ◽  
Vol 2 (1) ◽  
pp. 18-22
Author(s):  
Murlidhar Swami ◽  
Mona Narain ◽  
Krishna Kanwal
Keyword(s):  
Functional Impairment ◽  
Premenstrual Syndrome ◽  
Care Center ◽  
Tertiary Care ◽  
Premenstrual Dysphoric Disorder ◽  
Cross Sectional Study ◽  
Severe Form ◽  
Cross Sectional ◽  
Premenstrual Symptoms ◽  
Dsm Iv

ABSTRACT Introduction Premenstrual syndrome (PMS) and its more severe form “premenstrual dysphoric disorder (PMDD)” is a common yet underdiagnosed disorder. It is characterized by anxiety, mood changes, and several somatic symptoms in the last week of the luteal phase and began to remit within a few days after the onset of the follicular phase. Aims The aim of this study was to evaluate the prevalence of PMS and PMDD among females at a tertiary care center and evaluate the associated symptomatology, sociodemographic variables, and functional impairment. Materials and methods In an observational, cross-sectional study, 150 randomly selected females (18–30 years) were evaluated for menstrual history after sociodemographic profiling. Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV)-TR (SCID)-PMDD was applied among those who were positive on premenstrual symptoms screening tool. Statistical analysis was done using Statistical Package for the Social Sciences, version 14.0. Results The prevalence of PMS was 21.33%. Moderate to severe PMS was 14% and PMDD was 7.33% according to DSM-IV-TR criteria. Fatigue/lack of energy, decreased interest in work were the most commonly reported symptoms. Decreased school/work efficiency and productivity was the commonest form of functional impairment. Increased body mass index, onset of symptoms since menarche, duration of premenstrual symptoms, menstrual cramps, and family history showed statistically significant association with PMS/PMDD. Conclusion Premenstrual syndrome is fairly common and causes significant functional impairment. Screening females in relevant age group for its symptomatology may aid in early detection and better management. How to cite this article Swami M, Narain M, Kanwal K, Mishra M, Singh S. Premenstrual Syndrome: Correlation and Functional Impairment. J Mahatma Gandhi Univ Med Sci Tech 2017;2(1):18-22.

scholarly journals CONCEPT AND MANAGEMENT OF PREMENSTRUAL SYNDROME (MUTLAZIMA QABL HAIZ ) IN UNANI SYSTEM OF MEDICINE

2018 ◽  
Vol 8 (5-s) ◽  
pp. 122-125
Author(s):  
Sofia Naushin ◽  
Mubarak Ali ◽  
Dr Mustehasan
Keyword(s):  
Premenstrual Syndrome ◽  
Sleep Disturbances ◽  
Premenstrual Dysphoric Disorder ◽  
Modern Medicine ◽  
Severe Form ◽  
Emotional Disturbances ◽  
Potential Treatment ◽  
Unani Medicine ◽  
Physical Conditions ◽  
The World

Mutlazima Qabl Haiz (Premenstrual syndrome) refers to a combination of physical and emotional disturbances that occur after a woman ovulates and resolves with start of menstruation. More than 200 symptoms have been ascribed to PMS. Premenstrual Dysphoric Disorder ia a more severe form of premenstrual syndrome. The characteristic symptoms of premenstrual syndrome are mood swings, anxiety, and irritability and physical conditions – like headache, fatigue, bloating, sleep disturbances, nausea, and breast tenderness. 90% of the women all over the world experience these symptoms during their reproductive years. The PMS has unknown cause and does not have any specific proved diagnosis and medication in modern medicine. The main objective of this article is to review the potential treatment for premenstrual syndrome in unani medicine. Keywords: Premenstrual Syndrome, Premenstrual Dysphoric Syndrome, Unani Management

Premenstrual syndrome and premenstrual dysphoric disorder: cognitive behavioral therapy as treatment

2017 ◽  
Vol Ano 7 ◽  
pp. 15-23
Author(s):  
Leiliane Aparecida Diniz Tamashiro ◽  
Bianca Cristina Tunes Nakad ◽  
Joel Rennó ◽  
Antônio Geraldo da Silva ◽  
Renan Rocha ◽  
...  
Keyword(s):  
Cognitive Behavioral Therapy ◽  
Premenstrual Syndrome ◽  
Behavioral Therapy ◽  
Premenstrual Dysphoric Disorder ◽  
Cognitive Behavioral

Objetivo: Elucidar as principais hipóteses atuais sobre o transtorno disfórico pré-menstrual (TDPM), a síndrome pré-menstrual (SPM) e a terapia cognitiva comportamental (TCC) como tratamento. Método: Foi realizada uma pesquisa nos bancos de dados PubMed, Cochrane e BIREME (LILACS/BVS), nos idiomas português, espanhol e inglês, no período de 2000 a 2017, utilizando os seguintes descritores: transtorno disfórico pré-menstrual, síndrome prémenstrual e terapia cognitiva comportamental. Resultados: Um total de 107 estudos enquadrou-se nos critérios de inclusão – artigos de revisão da literatura, estudos do tipo corte transversal, estudos do tipo coorte prospectivo e estudo do tipo coorte retrospectivo. Cento e cinco estudos identificaram fatores fundamentais para o desenvolvimento da TDPM – as hipóteses da função ovariana, função hormonal, neurotransmissores, genética e fatores ambientais e vulnerabilidade. Desde 2009, temos estudos sobre a TCC como tratamento de primeira linha. Conclusão: Os fundamentos do TDPM podem ser vistos como uma complexa multiplicidade de fatores. Ainda não há nada conclusivo; futuras pesquisas são necessárias para definir os processos etiopatogênicos do TDPM. A TCC demonstrou sua eficácia como tratamento de primeira linha para SPM e TDPM.

Premenstrual Syndrome and Premenstrual Dysphoric Disorder in Japanese Collegiate Athletes

2015 ◽  
Vol 28 (4) ◽  
pp. 215-218 ◽  
Author(s):  
Takashi Takeda ◽  
Yoko Imoto ◽  
Hiroyo Nagasawa ◽  
Miyuki Muroya ◽  
Masami Shiina
Keyword(s):  
Premenstrual Syndrome ◽  
Collegiate Athletes ◽  
Premenstrual Dysphoric Disorder

MENSTRUAL PROBLEMS AMONG ADOLESCENT GIRLS (10-19YEARS) IN THE PRIMARY CARE SETTING

2021 ◽  
pp. 40-42
Author(s):  
Manjula M ◽  
M.K.C. Nair ◽  
Babu George ◽  
Leena M L ◽  
Preeja B
Keyword(s):  
Primary Care ◽  
Reproductive Health ◽  
Adolescent Girls ◽  
Premenstrual Syndrome ◽  
Social Life ◽  
Care Setting ◽  
Primary Care Setting ◽  
Premenstrual Dysphoric Disorder ◽  
Primary Data ◽  
Daily Routine

Background: Menstrual problems are common among adolescent girls which can affect their daily routine and quality of life. Early detection and intervention for the menstrual problems can improve future reproductive health. Aims: To nd the prevalence and type of menstrual disorders, premenstrual syndrome and premenstrual dysphoric disorder among adolescents in the primary care setting. This was a community based cross sectional survey done covering Materials and methods: the whole of Thiruvananthapuram district, Kerala..Anganwadis were the primary data collecting units, selected by systematic random sampling. Data was collected using pretested structured questionnaire and validated premenstrual symptoms screening tool. Mean, standard deviation and simple percentage were used. Chi square test was used for nding associations and signicance level. P value <0.05 was taken as signicant. The most common reported Results: problems during menstruation were dysmenorrhoea (73.6%), moderate to severe premenstrual syndrome (13.5%), oligomenorrhoea (12.5%), menorrhagia (8.4%) and premenstrual dysphoric disorder (6.2%).The prevalence of menstrual problems increased as the age increased Conclusions: Majority of adolescents suffer from one or other menstrual problem which can affect their academic and social life. It can also affect their future reproductive health. So school health programs should give emphasis on adolescent menstrual health for a healthy future generation.

Sign in / Sign up

Export Citation Format

Share Document